Humana Inc (HUM) Given Average Recommendation of “Buy” by Analysts
Humana Inc (NYSE:HUM) has been given an average rating of “Buy” by the twenty ratings firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $317.53.
Several equities analysts have commented on HUM shares. Cantor Fitzgerald reissued a “hold” rating and set a $250.00 target price on shares of Humana in a research report on Monday, April 23rd. Oppenheimer lifted their price target on shares of Humana from $305.00 to $311.00 and gave the stock an “outperform” rating in a report on Thursday, May 3rd. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, May 18th. Citigroup reaffirmed a “buy” rating and issued a $340.00 price target (up previously from $280.00) on shares of Humana in a report on Friday, June 1st. Finally, ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a report on Saturday, June 2nd.
In related news, insider William Kevin Fleming sold 15,637 shares of Humana stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $293.08, for a total value of $4,582,891.96. Following the completion of the transaction, the insider now directly owns 15,650 shares in the company, valued at approximately $4,586,702. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elizabeth D. Bierbower sold 3,092 shares of Humana stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the completion of the transaction, the insider now owns 14,289 shares of the company’s stock, valued at $4,715,370. The disclosure for this sale can be found here. Insiders sold a total of 108,068 shares of company stock worth $33,185,697 in the last ninety days. 0.60% of the stock is currently owned by insiders.
Humana stock opened at $324.62 on Friday. Humana has a 52 week low of $231.90 and a 52 week high of $331.09. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $44.78 billion, a price-to-earnings ratio of 27.72, a PEG ratio of 1.62 and a beta of 0.93.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The firm had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. During the same quarter last year, the firm earned $3.49 EPS. sell-side analysts expect that Humana will post 14.18 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 26th. Investors of record on Friday, September 28th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.62%. Humana’s dividend payout ratio (DPR) is presently 17.08%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Recommended Story: What is the NASDAQ?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.